Abstract. Sinomenine has been used to treat autoimmune diseases for centuries. However, little is known about its exact mechanisms of action. Whether sinomenine has an effect on programmed death-1 (PD-1) ligands (PD-Ls) in vivo remains unclear. The present study aimed to determine the effect of sinomenine on the expression of PD-L1 and PD-L2 in peripheral blood mononuclear cells (PBMCs). A total of 25 patients with mesangial proliferative nephritis (MsPGN) were treated with sinomenine and followed up for 3 months. The expression of PD-L1 and PD-L2 was studied by using real-time RT-PCR and flow cytometric analysis, and recorded at months 0, 1 and 3 within the PBMCs. The intra-renal expression of PD-L1 and PD-L2 was studied by immunohistochemistry. The results revealed that the PBMCs from the MsPGN patients expressed high levels of PD-L1 at the mRNA and protein levels compared with the healthy donors. Immunohistochemistry revealed an increased PD-L1 expression in the renal tissues from the MsPGN patients. Sinomenine was observed to have a significant effect in decreasing the PD-L1 expression in the PBMCs. The present study therefore suggests a novel mechanism for the therapeutic effects of sinomenine on MsPGN in vivo.
Introduction
Sinomenine (7,8-didehydro-4-hydroxy-3,7-dimethoxy-17-methylmorphinan-6-one) is a pure alkaloid extracted from the Chinese medicinal plant Sinomenium acutum. Previous studies demonstrated that the pharmacological properties of sinomenine included immunosuppression, anti-inflammation and arthritis amelioration (1, 2) . Due to these beneficial effects and the low incidence of side-effects, sinomenine has been used for the treatment of various diseases, particularly rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), renal allograft rejection and chronic glomerulonephritis (GN) (3) (4) (5) (6) . Although sinomenine is effectively used in the clinic and is gaining international popularity, its exact mechanism of action is not completely understood.
Observations from inflammatory renal diseases, including the occurrence of allograft rejection, tubulointerstitial nephritis and GN, have emphasized the key role of T cells in the injurious renal immune response (7, 8) . It is accepted that signals provided by the T-cell receptor (TCR)-peptide-major histocompatibility complex (MHC) and co-stimulatory molecules are required for the optimal activation of T cells (9, 10) . Selective manipulation of co-stimulatory molecules has been demonstrated to be beneficial in the treatment of autoimmune diseases, tumor and transplantation rejection (11, 12) . The programmed death-1 (PD-1)/PD-ligand (PD-L) pathway has been extensively characterized. Based on results from PD-1 -/-mice, PD-1 may be crucial in maintaining peripheral tolerance (13) . PD-L1 and PD-L2 are ligands for PD-1. The role of PD-L1 in regulating T-cell responses is controversial. However, overwhelming evidence supports the theory that PD-L1 is a negative regulator of T-cell response through either engagement with PD-1 or an unidentified receptor (14, 15) . Nevertheless, previous studies indicated that PD-L1 was able to stimulate T cell activation (16, 17) . Whether sinomenine has an immunoregulatory effect on PD-L1 and PD-L2 has, however, not been investigated.
In the present study, patients with mesangial proliferative nephritis (MsPGN), one of the most common pathological types of chronic GN, were examined. To elucidate the potential immunoregulatory properties of sinomenine, the patients were treated and then examined to determine the effects of sinomenine on the expression of PD-L1 and PD-L2 by examining peripheral blood mononuclear cells (PBMCs).
Subjects and methods
Antibodies and reagents. The mouse anti-human APC-PD-L1 (clone MIH1), PE-PD-L2 (clone MIH1), PerCP/Cy5. Blood biochemical parameters and proteinuria detection. Blood preparations and urine aliquots were collected at months 0, 1 and 3 during the course of the treatment with sinomenine. Creatinine, aminotransferase, and albumin levels were detected by an Olympus AU270 biochemical analyzer (Olympus, Tokyo, Japan). Complement C3 was detected by immunoturbidimetry using a Beckman Array 360 analyzer (Beckman Coulter, Miami, FL, USA). Simultaneously, the level of proteinuria was evaluated with a Sysmex UF-100 automated urinalysis analyzer (Sysmex, Kobe, Japan) and was graded semi-quantitatively from 0-3 (0, <0.15 g/l; 1, 0.15-0.3 g/l; 2, 0.3-1.0 g/l; and 3, 1.0-3.0 g/l).
Isolation of human PBMCs. Peripheral whole blood (4 ml) was collected into heparinized tubes. The human PBMCs were isolated via density gradient centrifugation using a lymphocyte separating medium according to the manufacturer's instructions. The isolated PBMCs were then lysed with TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA).
RNA extraction and quantitative real-time RT-PCR.
Total RNA was extracted from the lysed cells using TRIzol reagent, following the manufacturer's instructions. Real-time PCR was performed according to the Takara two-step real-time PCR protocol. Reverse transcription (RT) of the RNA was performed using PrimeScript™ RTase (Takara). The resulting cDNA was analyzed by real-time PCR with the ABI PRISM 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The primer sequences and the product size of each gene are reported in Table I . Quantification of the gene expression was performed using the 2 -∆∆Ct method (18) . The expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control to normalize the expression of target genes across the samples.
Flow cytometry. The PD-L1 and PD-L2 expression on the CD4 + and CD8 + T cells in the PBMCs was detected by flow cytometry. A total of 100 µl whole blood was stained with corresponding antibodies and 2 ml of H-lyse buffer was added to the blood. The surface expression of the immune molecules on the PBMCs was quantified with a FACScan flow cytometer (Becton Dickinson, Heidelberg, Germany). The FACS data were analyzed by using CELLQuestk software (BD Biosciences) and numbers indicated the mean fluorescence intensity (19) . Background fluorescence was measured in the cells treated with 100 µl staining buffer instead of the fluorescent antibodies. Appropriate isotype-matched antibodies from the manufacturer were used as specificity controls.
Immunohistochemistry of the renal biopsy. The intra-renal levels of PD-L1 and PD-L2 were determined by performing immunohistochemistry on the 3-µm paraffin-embedded tissues from the renal biopsies of the 25 patients with MsPGN. with the anti-PD-L1 (1:100) and anti-PD-L2 (1:100) antibodies overnight at 4˚C. This was followed by subsequent incubation with the secondary antibody, EnVision™ (EnVision™ system, HRP, mouse/rabbit; Dako, Denmark) for 30 min. Negative controls were obtained by omitting the primary antibodies or using irrelevant immunoglobulins. Reactivity was detected with a DAB Elite kit (K3465; Dako). PD-L1 and PD-L2 staining was graded semiquantitatively by noting the percentage of immunoreactive tubules (grade 0, no reactive tubules; grade 1, <20% of reactive tubules; grade 2, between 20 and 50% of reactive tubules; and grade 3, >50% of reactive tubules). The immunohistochemical grading was evaluated by 2 independent observers with good concordance.
Statistical analysis. All data are expressed as the means ± SEM. The independent samples t-test and χ 2 test were used for the continuous and categorical variables, respectively, in the comparison between the healthy donors and the MsPGN patients prior to treatment. A general linear model was used to examine the repeated measurement data. P<0.05 was considered to indicate a statistically significant difference.
Results

Patient characteristics and laboratory data.
The clinical diagnosis of MsPGN was made by the histological examination of each renal biopsy. Fig. 1 shows a patient renal biopsy slide with glomerular mesangial proliferation stained with PAS. The patients enrolled in the present study were the same individuals as in our previous study (20) . The average age and the gender distribution of the patients (35±3.11 years, 10 male/15 female) did not differ significantly from those of the healthy donors (30.4±0.83 years, 4 male/6 female). There were no differences in the serum levels of creatinine, urea nitrogen, albumin or aminotransferase between the patients and healthy donors. There were also no differences in the values of hemoglobin and white blood cells (WBCs) between the two groups. Sinomenine was observed to have no effect on these laboratory data. In total, three patients had a transient skin rash. Varying levels of proteinuria were observed in the treated patients (the level of proteinuria was graded semiquantitatively from 0-3; 3 patients were grade 3, 13 patients were grade 2 and 9 patients were grade 1 prior to treatment with sinomenine). At 1 month subsequent to initiation of the treatment with sinomenine, the proteinuria was ameliorated (11 patients were grade 2, 11 patients were grade 1 and 3 patients were grade 0). At 3 months, the amelioration of the proteinuria by sinomenine was more significant (3 patients were grade 2, 7 patients were grade 1 and 15 patients were grade 0).
Changes in the expression of the PD-L1 and PD-L2 mRNA in the PBMCs.
Quantitative real-time RT-PCR was used to measure the expression levels of the PD-L1 and PD-L2 mRNA in the PBMCs from the 10 healthy donors and 25 patients with MsPGN, at 0, 1 and 3 months subsequent to initiation of treatment with sinomenine. As shown in Fig. 2 , the PBMCs from the MsPGN patients expressed high levels of the PD-L1 (P=0.037) mRNA compared with the controls. There were no significant differences in the expression of PD-L2 mRNA between the MsPGN patients and the controls (P=0.627). The expression of the PD-L1 mRNA was suppressed by sinomenine. The decrease in the PD-L1 expression was detected at 1 (P=0.034) and 3 months (P=0.002). However, sinomenine did not affect the expression of the PD-L2 mRNA (P=1.000).
Change in the expression of the PD-L1 and PD-L2 protein in the PBMCs. The expression of the PD-L1 and PD-L2 molecules on the CD4
+ and CD8 + T cells in the PBMCs was investigated by using flow cytometry analysis. As shown in Fig. 3 , the constitutive expression of PD-L1 was detected on the CD4 + and CD8 + T cells in the PBMCs from the MsPGN patients and the healthy donors. However, the expression of PD-L2 was hardly detected on the CD4 + and CD8 + T cells in the PBMCs from the two groups. The patients with MsPGN were observed to have an increased PD-L1 expression on the CD4 + and CD8 + T cells in the PBMCs compared with the healthy donors. Overall, treatment with sinomenine significantly inhibited the high expression of PD-L1 on the CD4 + and CD8
+ T cells in the PBMCs from the MsPGN patients, whereas it had no effect on the expression of PD-L2. 
Intra-renal PD-L1 and PD-L2 protein expression.
The expression of PD-L1 and PD-L2 in the human renal biopsy tissue samples was detected by immunohistochemistry. As shown in Fig. 4 , a significant PD-L1 expression was detected in the tubular epithelium. Positive staining was detected in the cell membrane or cytoplasm or in the two together. However, the expression of PD-L1 was not observed in the glomeruli.
Patients with MsPGN were identified as having increased PD-L1 (P=0.012) expression in the renal biopsy tissues compared with normal individuals. The intensity levels of the PD-L1 expression in the normal or diseased renal tissues are shown in Table II . The expression of PD-L2 was not observed in the renal tissues of the MsPGN patients or the controls.
Discussion
To elucidate the potential immunoregulatory properties of sinomenine, its effect on the expression of the co-stimulatory molecules, the PD-1 ligands, by the PBMCs was investigated in the present study. The upregulation of PD-L1 was detected in the PBMCs from the MsPGN patients at the mRNA and protein levels. In contrast to PD-L1, the expression of PD-L2 in the PBMCs was hardly detected by flow cytometry in the MsPGN patients and the healthy donors, although the PD-L2 mRNA Table II . Intra-renal expression of PD-L1.
No. of positive cases -------------------------------------------------------------------------------Group
Grade 0 expression was observed. This translational suppression may be related to the different expression pattern of PD-L2, since the cell-surface expression of PD-L2 is limited to dendritic cells and macrophages, whereas PD-L1 is widely distributed in the lymphoid organs and non-lymphoid tissues (21, 22) . We previously observed significant PD-L1 staining in the renal tubules using immunohistochemistry in diseased kidneys suffering IgA nephropathy, interstitial nephritis or lupus nephritis (19) . In the present study, the high expression of PD-L1 was also detected in the tubular epithelium in the renal biopsy tissues from the MsPGN patients, suggesting that PD-L1 expression is upregulated in vivo in inflammatory kidneys. However, the expression of PD-L2 was not observed in the kidneys from the MsPGN patients. The differential expression patterns of PD-L1 and PD-L2 thus suggest different roles for these molecules in the pathogenesis of MsPGN.
While PD-L1 is associated with the negative regulation of T-cell responses via PD-1, several studies have indicated that PD-L1 was able to co-stimulate T-cell growth and cytokine production. These outcomes were produced when resting T cells were stimulated with suboptimal concentrations of anti-CD3 mAb, immobilized PD-L1-Ig moderately enhanced proliferation, strongly upregulated IL-10 production and modestly upregulated IFN-γ and GM-CSF production in both human and mouse systems (15, 23) . A noteworthy result was recorded in a study by Kanai et al (24) , which observed the expression profiles of the PD-1 ligands in human inflammatory bowel disease and a murine chronic colitis model. There was a significantly increased expression of PD-L1 on the T lymphocytes, B lymphocytes, macrophage and DCs in the inflamed colons of the inflammatory bowel disease patients and the colitic mice. However, the administration of the anti-PD-L1 mAbs suppressed the wasting disease and colitis, abrogated the leukocyte infiltration and reduced the production of interferon (IFN)-γ, interleukin (IL)-2, and tumor necrosis factor (TNF)-α in the lamina propria of the CD4 + T cells. These data suggested that the blockade of PD-L1 suppressed the development of chronic intestinal inflammation. In the present study, the high expression of PD-L1 in the PBMCs and renal biopsy tissues may correlate with the development of MsPGN.
Sinomenine has been widely used in China for the treatment of rheumatoid arthritis, renal allograft rejection and SLE (3) (4) (5) (6) . In the present study, the treatment with sinomenine led to significantly reduced proteinuria and elevated complement C3 levels, which demonstrated that sinomenine was able to effectively improve the clinical symptoms of the patients with MsPGN. Previous studies have demonstrated that sinomenine was able to regulate several immune functions, including i) reducing the production of TNF-α by activating macrophages; ii) inhibiting IL-8 and membrane (m)IL-2R and enhancing IL-6 production on the PBMCs; iii) inhibiting human CD4 + T-cell proliferation; iv) inducing apoptosis in the synoviocytes; and v) inhibiting maturation of the monocyte-derived dendritic cells (25) (26) (27) (28) (29) (30) .
In conclusion, sinomenine was an effective strategy for treating MsPGN through the downregulation of PD-L1 expression. These results suggest that sinomenine may be able to regulate the T-cell response by the inhibition of T-cell-associated PD-L1 expression.
